177lu-labeled di-hsg peptide imp288

177Lu-labeled di-HSG peptide IMP288 is a radiolabeled synthetic hapten-peptide designed for use in pretargeted radioimmunotherapy (PRIT) of cancer. It consists of a divalent histamine-succinyl-glycine (HSG) hapten-peptide conjugated to the macrocyclic chelator DOTA, which stably binds the therapeutic radionuclide lutetium-177 (¹⁷⁷Lu)[1][3][5]. The drug is administered after a bispecific monoclonal antibody that targets both a tumor-associated antigen (such as carcinoembryonic antigen [CEA] or TROP2) and HSG. After the antibody localizes to tumor tissue and clears from circulation, 177Lu-IMP288 is injected; it rapidly binds to the prelocalized antibody at the tumor site while unbound molecules are quickly excreted[7]. Lutetium-177 emits medium-energy beta particles suitable for treating small-volume disease with minimal radiation exposure to normal tissues[3][7]. This approach allows high tumor-to-normal tissue ratios and enables dosimetry-based personalized dosing[5][6]. Clinical studies have focused on advanced colorectal cancer and prostate cancer expressing CEA or TROP2 antigens[5][6][9].

Other names

DOTA-di-HSG peptide IMP288177Lu-DOTA-di-HSG-IMP288